Literature DB >> 16483851

Quality of life in medication-resistant epilepsy: the effects of patient's age, age at seizure onset, and disease duration.

Magdalena Szaflarski1, Jason M Meckler, Michael D Privitera, Jerzy P Szaflarski.   

Abstract

OBJECTIVE: The goal of this study was to examine the effects of age, age at seizure onset, and duration of epilepsy on health-related quality of life (HRQOL) in patients with medication-resistant epilepsy.
METHODS: We analyzed data for a sample of 99 patients with medication-resistant epilepsy drawn from admissions to the Epilepsy Monitoring Unit. Patients had completed the Quality of Life in Epilepsy-89 (QOLIE-89), Profile of Mood States (POMS), and Adverse Events Profile. Number of comorbidities and number of antiepileptic drugs were abstracted from the chart. The dependent variable was QOLIE-89 overall score. The data were analyzed using ordinary least-squares regression.
RESULTS: The simple regression results showed no significant effect of patient's age on QOLIE-89 (P=0.354), whereas age at onset and duration had significant effects (P=0.004 and P=0.012, respectively); the higher the age at onset and the shorter the disease duration, the lower the HRQOL. After adding POMS Depression/Dejection, Adverse Events Profile, comorbidities, and antiepileptic drugs, the effects of age at onset and duration were no longer significant (P=0.084 and P=0.207).
CONCLUSIONS: Adult-onset epilepsy can disrupt one's established social, economic, and psychological life, while better coping mechanisms and social support may improve HRQOL as the duration of epilepsy increases. The modest association of age at onset and disease duration with HRQOL is explained away by mood states and adverse events, which are much stronger predictors of HRQOL. Interventions to improve HRQOL in patients with medication-resistant epilepsy should, therefore, focus on treating mood disturbances and minimizing medication side effects.

Entities:  

Mesh:

Year:  2006        PMID: 16483851     DOI: 10.1016/j.yebeh.2006.01.001

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  6 in total

1.  Associations between illness duration and health-related quality of life in specified mental and physical chronic health conditions: results from a population-based survey.

Authors:  Lucy Busija; Jeretine Tan; Kerrie M Sanders
Journal:  Qual Life Res       Date:  2017-05-12       Impact factor: 4.147

2.  Association of demographic, clinical and treatment variables with quality of life of patients with epilepsy in Greece.

Authors:  Charitomeni Piperidou; Anna Karlovasitou; Nikolaos Triantafyllou; Evagelia Dimitrakoudi; Aikaterini Terzoudi; Eleni Mavraki; Grigorios Trypsianis; Konstantinos Vadikolias; Ioannis Heliopoulos; Dimitrios Vassilopoulos; Stavros Balogiannis
Journal:  Qual Life Res       Date:  2008-07-29       Impact factor: 4.147

3.  Health-related quality of life in adults with epilepsy: the effect of age, age at onset and duration of epilepsy in a multicentre Italian study.

Authors:  Valeria Edefonti; Francesca Bravi; Katherine Turner; Ettore Beghi; Maria Paola Canevini; Monica Ferraroni; Ada Piazzini
Journal:  BMC Neurol       Date:  2011-03-10       Impact factor: 2.474

4.  Comparison of the health-related quality of life between epileptic patients with partial and generalized seizure.

Authors:  Nahid Ashjazadeh; Golnaz Yadollahikhales; Anaheed Ayoobzadehshirazi; Nazanin Sadraii; Negin Hadi
Journal:  Iran J Neurol       Date:  2014-04-03

5.  Validation of the integrative model of adjustment to chronic conditions: Applicability to adult-onset epilepsy.

Authors:  L D Hammond; A P Farrington; S Kılınç
Journal:  Health Psychol Open       Date:  2019-11-07

6.  Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center.

Authors:  Mariacarolina Vacca; Mariana Fernandes; Matteo Spanetta; Fabio Placidi; Francesca Izzi; Caterina Lombardo; Nicola Biagio Mercuri; Claudio Liguori
Journal:  Neurol Sci       Date:  2021-09-15       Impact factor: 3.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.